



Our STN: BL 102707/5099

**SUPPLEMENT APPROVAL**  
**June 12, 2020**

Immucor, Inc.  
Attention: Mr. Howard Yorek  
3130 Gateway Drive  
Norcross, GA 30071

Dear Mr. Yorek:

We have approved your request submitted March 19, 2020, received March 20, 2020, to supplement your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Reagent Red Blood Cells, Product Code QHT, to add the automated Non-ABO titration assay to the Panoscreen and Panoscreen Extend indications for use on the NEO Iris.

## **LABELING**

We hereby approve the draft package insert labeling submitted under amendment 5003, dated June 5, 2020. This is a reminder that as of September 24, 2014, medical devices that are licensed under the PHS Act are subject to certain provisions of the final Unique Device Identifier (UDI) rule. These provisions include the requirement to provide a UDI on the device label and packages (21 CFR 801.20), format dates on the device label in accordance with 21 CFR 801.18, and submit data to the Global Unique Device Identification Database (GUDID) (21 CFR 830 Subpart E). Additionally, please identify each device identifier implemented for the subject device, and the device identifiers that have been discontinued for the subject device as a labeling change in an annual report consistent with 21 CFR 601.12(f)(3). For more information on these requirements, please see the UDI website at <http://www.fda.gov/udi>.

Please submit all final printed labeling as PDF electronic copy (eCopy) at the time of use and include implementation information on Form FDA 356h as appropriate.

Two draft copies of the proposed introductory advertising or promotional labeling may be voluntarily submitted for advisory comment with a completed Form FDA 2253 to the Advertising and Promotional Labeling Branch.

In response to the COVID-19 public health emergency, CBER's Document Control Center (DCC) will not process any submission received by mail or courier including submissions provided on paper and electronic media (e.g., CDs, USB) after Wednesday, April 29, 2020 until further notice. Device submissions, for CBER regulated devices, can still be submitted electronically using the Electronic Submissions

Gateway (ESG) (under 10GB) or in some cases via email (under 150MB) in accordance with final industry guidance, eCOPY Program for Medical Devices Submissions found at <https://www.fda.gov/media/83522/download>. CBER strongly encourages sending submissions through the ESG, FDA's preferred secure method of transmission. Instructions for setting up an ESG account can be found at <https://www.fda.gov/industry/electronic-submissions-gateway>.

Submissions regarding this file may also be submitted electronically via email at [CBERDCC\\_eMailSub@fda.hhs.gov](mailto:CBERDCC_eMailSub@fda.hhs.gov). We will accept submissions through this email option only during the COVID-19 public health emergency. For additional information regarding CBER operations during this public health emergency, please see the CBER COVID -19 CBER Regulated Biologics page found at <https://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulated-biologics>.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Orieji Illoh, MD  
Director  
Division of Blood Components and Devices  
Office of Blood Research and Review  
Center for Biologics Evaluation and Research